These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In Silico Approach for Phytocompound-Based Drug Designing to Fight Efflux Pump-Mediated Multidrug-Resistant Mycobacterium tuberculosis. Biswas SS; Browne RB; Borah VV; Roy JD Appl Biochem Biotechnol; 2021 Jun; 193(6):1757-1779. PubMed ID: 33826064 [TBL] [Abstract][Full Text] [Related]
5. Virtual screening studies to identify novel inhibitors for Sigma F protein of Mycobacterium tuberculosis. Mustyala KK; Malkhed V; Chittireddy VR; Vuruputuri U Int J Mycobacteriol; 2015 Dec; 4(4):330-6. PubMed ID: 26964817 [TBL] [Abstract][Full Text] [Related]
6. Molecular modelling and competitive inhibition of a Mycobacterium tuberculosis multidrug-resistance efflux pump. Scaini JLR; Camargo AD; Seus VR; von Groll A; Werhli AV; da Silva PEA; Machado KDS J Mol Graph Model; 2019 Mar; 87():98-108. PubMed ID: 30529931 [TBL] [Abstract][Full Text] [Related]
7. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing. Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis. Kumar M; Singh K; Naran K; Hamzabegovic F; Hoft DF; Warner DF; Ruminski P; Abate G; Chibale K ACS Infect Dis; 2016 Oct; 2(10):714-725. PubMed ID: 27737555 [TBL] [Abstract][Full Text] [Related]
9. Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: A Rational Drug Design Perspective. Kapp E; Malan SF; Joubert J; Sampson SL Mini Rev Med Chem; 2018; 18(1):72-86. PubMed ID: 28494730 [TBL] [Abstract][Full Text] [Related]
10. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase. Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243 [TBL] [Abstract][Full Text] [Related]
11. Computationally Guided Identification of Novel Mycobacterium tuberculosis GlmU Inhibitory Leads, Their Optimization, and in Vitro Validation. Mehra R; Rani C; Mahajan P; Vishwakarma RA; Khan IA; Nargotra A ACS Comb Sci; 2016 Feb; 18(2):100-16. PubMed ID: 26812086 [TBL] [Abstract][Full Text] [Related]
12. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. Ekins S; Kaneko T; Lipinski CA; Bradford J; Dole K; Spektor A; Gregory K; Blondeau D; Ernst S; Yang J; Goncharoff N; Hohman MM; Bunin BA Mol Biosyst; 2010 Nov; 6(11):2316-2324. PubMed ID: 20835433 [TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach. Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549 [TBL] [Abstract][Full Text] [Related]
14. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494 [TBL] [Abstract][Full Text] [Related]